Inhibikase Therapeutics Inc. (IKT)’s stock has witnessed a price hike of 13.19% from the previous close with its current price standing at $1.03. Its current price is -32.24% under its 52-week high of $1.52 and 134.04% more than its 52-week low of $0.44. Based on the past 30-day period, the stock price is -5.82% below the high and +142.22% above the low.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, IKT’s SMA-200 is $0.8122.
Additionally, it is important to take into account IKT stock ratios, including its price-to-sales ratio, which is 357.12 for the last tewlve months.IKT’s price to book ratio for the most recent quarter was 0.91, resulting in an 0.83 price to cash per share for the period.
How does Inhibikase Therapeutics Inc. (IKT) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
Inhibikase Therapeutics Inc. (IKT): Earnings History
If we examine Inhibikase Therapeutics Inc.’s recent earnings history, in the last quarter ended on 9/29/2022, it posted adjusted earnings per share of -$0.18, slashing the consensus of -$0.18. In other words, it beat the consensus by $0, resulting in a 0.00% surprise. In the 3 months period before the previous quarter which was closed on 9/29/2022, the stock recorded adjusted earnings per share of -$0.18 in contrast with the Outlook of -$0.18. That was a difference of $0 and a surprise of 0.00%.
Inhibikase Therapeutics Inc. (NASDAQ: IKT) Ownership Details
I will give a breakdown of the key shareholders in Inhibikase Therapeutics Inc. (IKT). Recent figures show that the company’s insiders hold 21.32% of shares. A total of 25 institutional investors hold shares in the company, making 18.26% of its stock and 23.20% of its float.
Sep 29, 2022, it was reported that the Company’s largest institutional holder is ACT Capital Management, LLC holding total of 0.94 million shares that make 3.72% of the company’s total number of shares and are currently priced at 0.96 million.
The securities firm Vanguard Group, Inc. (The) holds 0.53 million shares of IKT, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 2.10%, and the holding percentage of shares is valued at 0.54 million.
An overview of Inhibikase Therapeutics Inc.’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Inhibikase Therapeutics Inc. (IKT) traded 327,347 shares per day, with a moving average of $0.6294 and price change of +0.60. With the moving average of $0.5942 and a price change of +0.61, about 180,169 shares changed hands on average over the past 50 days. Finally, IKT’s 100-day average volume is 141,512 shares, alongside a moving average of $0.7166 and a price change of +0.13.
